Form 4: Novavax Executive Mark Casey Reports Stock Transactions
SEC Form 4 Filing
EVP and Chief Legal Officer of Novavax, Mark J. Casey, reports the vesting and disposal of restricted stock units and common stock.
Summary
- Mark J. Casey, EVP and Chief Legal Officer of Novavax, filed a Form 4 detailing changes in beneficial ownership.
- On March 1, 2025, 4,000 restricted stock units (RSUs) vested and were converted into common stock.
- Casey disposed of 1,214 shares of common stock to cover tax obligations at a price of $8.33 per share.
- Following these transactions, Casey directly owns 31,973 shares of Novavax common stock and 8,000 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions have a minimal impact on stakeholders as they represent routine executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of RSU vesting and stock disposal |
| 03/04/2025 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.